Relay ‘full steam ahead’ on PI3K inhibitor fueled by first phase 2 data in blood vessel disorder

Relay Therapeutics reported 60% volumetric response at 12 weeks in 20 evaluable patients in its phase 2 vascular anomalies study of zovegalisib, with 95% showing some lesion reduction and symptom improvements of 89%, 79% and 71% across key endpoints. Safety also looked manageable, with no grade 3 hyperglycemia or diarrhea and no AE-related discontinuations, though Relay dropped the 400 mg twice-daily dose for this indication after an unfavorable safety profile. The data support Relay’s dual-track development strategy in vascular anomalies and breast cancer, but the readout remains early-stage and not yet a pivotal value inflection.

Analysis

RLAY is starting to separate its PI3Kα franchise from the historical “class toxicity” discount that has capped every prior asset in the space. The key signal is not just activity, but activity at doses that appear compatible with chronic use; that matters because vascular anomalies are a long-duration, symptom-driven market where durability and tolerability matter more than maximal tumor shrinkage. If the safety profile holds, the market is likely underestimating how quickly this can become a label-expansion story rather than a one-off rare-disease readout.

The competitive implication is more meaningful for Celcuity than for the larger incumbents. Celcuity’s near-term launch is still advantaged in breast cancer because it has a more immediate commercial path, but RLAY is now creating a differentiated second indication that could improve investor willingness to underwrite a multi-asset pipeline value rather than a single oncology binary. That reduces the probability that breast-cancer disappointment alone collapses the equity, while also forcing competitors to prove not just efficacy, but clean tolerability at repeat dosing.

The biggest second-order effect is on capital allocation and perception: a rare-disease proof point can materially improve partnering optionality or internal financing terms if the company later needs to fund the breast cancer program through a slower launch curve. The main risk is that this dataset is still small and enriched by early responders; any signal of dose-limiting hyperglycemia, diarrhea, or discontinuations in the expansion cohorts would immediately reprice the thesis because the entire differentiation hinges on chronic safety. The catalyst sequence is months, not days: more mature VA data, then breast-cancer phase 3 execution, with the next 1-2 quarters being decisive for whether this becomes a platform reset or just a transient sympathy move.

Key Decisions for Investors

• Initiate a tactical long RLAY position on pullbacks over the next 1-3 weeks; the setup offers asymmetric upside if follow-up VA data confirm durability, with downside capped by the fact that the current readout already de-risks the core safety narrative.
• Pair trade: long RLAY / short CELC into the next 4-8 weeks; CELC has the cleaner near-term commercial event, but RLAY now has a differentiated catalyst path that the market is likely to re-rate only after additional data.
• Consider buying RLAY call spreads 3-6 months out; the trade monetizes upside from sequential VA and breast-cancer updates while limiting premium burn if the story stalls.
• Avoid shorting NVS/AZN on this headline alone; the readthrough to incumbents is limited because their products are already established and the main loser is not share, but the narrative around class-wide safety.
• If RLAY rallies sharply on low-volume sympathy, trim into strength rather than chase; the core risk remains small-N noise until larger expansion cohorts validate the low-grade AE profile.